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Kidney Disease Stages 3 and 4: Efﬁcacy, Safety,
and Effect on Serum Calciﬁcation Propensity—
A Prospective Randomized Double-Blinded
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Introduction: Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and
mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg)
can slow or even prevent the development of vascular calciﬁcation seen in CKD. Serum calciﬁcation
propensity (T50) is a novel functional test, which is associated with all-cause mortality in CKD
and measures the ability of serum to delay the formation of crystalline nanoparticles. Theoretically,
increasing serum Mg should improve T50 and thereby reduce the propensity towards ectopic
calciﬁcation.
Methods: We conducted a randomized placebo-controlled double-blinded clinical trial to investigate the
safety of 2 different doses of oral Mg supplementation in subjects with CKD stages 3 and 4 as well as their
effects on intracellular Mg and T50. Thirty-six subjects with CKD stages 3 and 4 were randomized to one
of 3 groups (placebo, elemental Mg 15 mmol/d or elemental Mg 30 mmol/d) given as slow-release Mg
hydroxide and followed for 8 weeks.
Results: Thirty-four subjects completed the trial. Intracellular Mg remained stable throughout the trial
despite signiﬁcant increases in both serum and urine Mg. T50 increased signiﬁcantly by 40 min
from 256  60 (mean  SD) to 296  64 minutes (95% conﬁdence interval, 11–70, P < 0.05) in the Mg
30 mmol/d group after 8 weeks. No serious adverse events related to the study medication were reported
during the study.
Discussion: Oral Mg supplementation was safe and well tolerated in CKD stages 3 and 4 and improved T50,
but did not increase intracellular Mg. Further studies are needed to investigate the long-term effects of Mg
supplementation in CKD stage 3 and 4 and whether improvement in calciﬁcation propensity is related to
clinical endpoints.
Kidney Int Rep (2017) 2, 380–389; http://dx.doi.org/10.1016/j.ekir.2016.12.008
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C hronic kidney disease (CKD) affects approximately13% of the general population1 and is associated
with increased risk of cardiovascular disease (CVD)
because of both traditional and nontraditional CVD risk
factors.2 Among the nontraditional CVD risk factors,
disturbances in mineral and bone disease are associated
with vascular calciﬁcation,3 which is associated with
increased cardiovascular mortality in end-stage renal
disease.4 Key factors in this regard are phosphate (PO4)
and calcium (Ca), which can precipitate and induce an
osteogenic transformation in the vascular smooth
muscle cells of the arteries causing them to calcify and
stiffen.3
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Epidemiological studies have found associations
between higher levels of serum magnesium (Mg) and
improved survival among patients suffering from
CKD5 and end-stage renal disease,6–13 and higher
levels of serum Mg (sMg) are associated with reduced
progression of CKD.5,14 These associations are
thought to be mediated by an antagonistic effect of
Mg on the procalcifying milieu in CKD.15 In vitro
calciﬁcations induced by Ca and high concentrations
of PO4 can be prevented or reversed by adding or
increasing Mg, which appears to be mediated by both
upregulation of factors that inhibit calciﬁcation and
downregulation of factors that promote calciﬁca-
tion.16–20 Also, 2 small clinical trials of Mg supple-
mentation in end-stage renal disease have shown
reduced progression of vascular calciﬁcation.21,22
Thus, Mg supplementation could potentially be a
therapeutic option to attenuate the progression of
vascular calciﬁcation in CKD. Because studies have
shown that inﬂux of Mg into the vascular smooth
muscle cell is important for prevention of vascular
calciﬁcation,16,18,19 measurement of any effect of Mg
therapy on intracellular Mg (iMg) would be of in-
terest. However, because of the renal excretion of
Mg, there is a risk that Mg therapy might result in
toxic hypermagnesemia in patients with reduced
kidney function. So far, no studies have examined
the effect of oral Mg supplementation on iMg in
subjects with CKD stages 3 and 4, or the safety of this
intervention.
Serum calciﬁcation propensity (T50) is a novel
functional test, which determines the ability of serum
to resist Ca/PO4 precipitation by measuring the time-
point of conversion from primary to secondary calci-
protein particle.23 Previous studies have shown that
low T50 predicts all-cause mortality in CKD stages 3
and 424 and kidney transplant recipients,25,26 as well
as graft failure in kidney transplant recipients.25 T50 is
believed to reﬂect the propensity towards ectopic
calciﬁcation, although so far low T50 has not been
directly associated with progression of vascular
calciﬁcation. In vitro data indicate that Mg improves
T50,
23 but so far this has not been examined in a
clinical trial.
We conducted a randomized placebo-controlled
double-blinded clinical trial to investigate the efﬁcacy
and safety of 2 different doses of oral Mg supplemen-
tation on iMg in subjects with CKD stages 3 and 4, as
well as any effects on T50. We hypothesized that
greater doses of Mg supplementation would result in a
greater increase in iMg compared with placebo as well
as improving T50 in subjects with CKD stages 3 and 4
and low or low-normal sMg.
METHODS
Subjects
Subjects were recruited between October 2014 and
February 2015 from the outpatient clinic at the Division
of Nephrology, Roskilde County Hospital, Denmark. All
patients were screened before planned visits to the clinic
and those matching trial criteria were offered partici-
pation in the trial. Inclusion criteria were age> 18 years,
estimated glomerular ﬁltration rate (eGFR) < 60 ml/min
per 1.73 m2, total sMg< 0.82 mmol/l, safe contraceptive
treatment in women of childbearing age, and written
informed consent. Exclusion criteria were current
treatment with hemodialysis or peritoneal dialysis,
kidney transplant recipient, treatment with Mg-
containing medication or supplements, parathyroid
hormone (PTH) > 66 rmol/l, cancer, other medical
condition that in the opinion of the investigators would
prohibit participation in the trial, pregnancy or breast-
feeding, allergies to any contents of the study medica-
tion, and participation in other interventional trials.
Design
The trial was an investigator-initiated double-blinded
placebo-controlled clinical trial in which subjects
were randomized in a ratio of 1:1:1 to 8 weeks of oral
treatment with either placebo twice daily, slow-
release Mg hydroxide 360 mg (equivalent to
15 mmol of elemental Mg) (Mablet, Gunnar Kjems
ApS, Copenhagen, Denmark) once daily and placebo
once daily, or slow-release Mg hydroxide 360 mg
twice daily. Mg hydroxide and placebo tablets were
identical in appearance, constituents, and containers,
and did not contain Ca. Study medication was packed
in consecutively numbered containers according to a
computer generated block-randomized randomization
list, and was administered to subjects consecutively as
they entered the trial. Subjects and investigators were
blinded to the study medication during the course of
the trial.
At weeks 0, 4, and 8, sublingual epithelial cells were
sampled for iMg and nonfasting blood samples, 24-hour
urine samples were collected, and an electrocardiogram
was performed. Subjects were instructed to maintain
their usual diets and not to begin treatment with Mg-
containing medication or supplements for the dura-
tion of the trial. Adherence was assessed by pill count
at week 8.
The primary endpoint was a change in iMg as
assessed by energy dispersive X-ray microanalysis of
sublingual epithelial cells,27 as this has been shown
previously to correlate with iMg in human atrial car-
diomyocytes.28 Based on previous studies,29–33 an
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increase in iMg of 2.0 mEq/l with a SD of 2.0 mEq/l was
considered clinically relevant. With a probability of
type 1 error (a) of 5% and power of 80% (1  b) a
sample size of 10 subjects per group would be neces-
sary to detect a difference of 2.0 mEq/l. A dropout rate
of 15% was anticipated, and therefore 36 subjects in
total were included in the trial (12 subjects per group).
Dropouts were not replaced.
Secondary endpoints were blood levels of total
Mg, PO4, ionized Ca, PTH, 25-hydroxy vitamin D3
(25-OH-D3), T50, fetuin-A, albumin, bicarbonate,
intact ﬁbroblast growth factor 23 (FGF23), eGFR,
24-hour urinary Mg (uMg) and PO4 (uPO4), and
electrocardiogram-measured QTc interval.
Ethics
The trial is in compliance with the Helsinki Declaration
II of 1975, revised 1983, and was approved 5 May 2014
by the Danish National Committee on Biomedical
Research Ethics (SJ-398) and the Danish Data Protection
Agency. The trial was registered at ClinicalTrials.gov
(NCT02216877). All subjects gave written informed
consent before initiating the trial.
Laboratory Analysis
iMg was measured in sublingual epithelial cells scraped
from the mucosa adjacent to the frenulum and imme-
diately ﬁxed on a carbon slide with cytology ﬁxative.
The slides were examined with a scanning electron
microscope (FEI; Thermo Fisher Scientiﬁc, Waltham,
Massachusetts), and suitable cells were identiﬁed. iMg
was measured with radiographic analysis of individual
epithelial cells (EXA; Intracellular Diagnostics, Med-
ford, Oregon) (normal range 34.0–42.0 mEq/l). Re-
ported values are the mean of 5 to 10 cells per subject; a
specimen was rejected if variance exceeded 2%. This
method is used to assess total cellular magnesium and
cannot differentiate free Mg from bound species.
Blood samples were drawn from subjects in non-
fasting states. Samples for measurement of T50,
fetuin-A, and FGF23 were collected and immediately
stored at –80C. The analyses were performed in bulk
in the same analytical run so as to eliminate interassay
variation. Blood levels of total Mg, ionized Ca, PO4,
PTH, 25-OH-D3, creatinine, hemoglobin, bicarbonate,
and albumin were measured on a routine basis by the
same standardized methods at the local department of
clinical biochemistry. Urine samples were collected
over 24 hours in 2.5-liter containers, which contained
100 ml of 2.5% hydrochloric acid. uMg and uPO4 were
analyzed on a routine basis by the same standardized
analysis at the local laboratory.
T50 was measured using a standardized method
previously described.23 FGF23 was measured using the
human intact FGF23 ELISA kit 60-6500 (Immutopics,
San Clemente, CA), and fetuin-A was measured using
the human intact Quantikine human Fetuin A ELISA
kit DFTA00 (R&D Systems, Minneapolis, MN). PTH
was measured using the second-generation intact PTH
immunoassay (reference values 1.5–7.6 rmol/l) (ADVIA
Centaur, Siemens, Erlangen, Germany). eGFR was
calculated using the CKD-EPI formula.
Statistical Analysis
The biostatistical evaluation was performed blinded
using SPSS version 22.0.0.0 (IBM Corporation,
Armonk, NY). Continuous data were described as
mean  SD for data of a normal distribution, and as
median and interquartile range (25th–75th percentile)
for data of a non-normal distribution. For assessment
of within-group changes, a one-way analysis of
variance with repeated measures or a Friedman test
(both with post hoc Bonferroni correction for multi-
ple measures) was applied for data with Normal or
non-Normal distributions, respectively. For assess-
ment of between-group changes of iMg, sMg, uMg,
and T50, a mixed 2-way analysis of variance with
repeated measures was applied. All tests were 2-sided
tests and a P < 0.05 was considered statistically
signiﬁcant.
RESULTS
Ninety-two subjects met inclusion criteria for the trial,
and of these, 36 agreed to participate (Figure 1).
Demographic characteristics of trial subjects are dis-
played in Table 1. According to tablet count at ﬁnal
follow-up visit compliance >95% was achieved in all
subjects.
Figure 1. CONSORT diagram. Mg, magnesium.
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The primary study endpoint, iMg, did not change
signiﬁcantly compared with week 0 in any of the groups
at either week 4 or week 8 (Table 2 and Figure 2a). sMg
and uMg increased signiﬁcantly from week 0 to week 4
in both Mg treatment groups, whereas there was no
change in the placebo group (Table 2 and Figure 2b
and c). At week 8, both sMg and uMg increased further
compared with week 0 in the Mg 30 mmol/d group,
whereas in the Mg 15 mmol/d group, only uMg was
increased compared with week 0 and the change in sMg
was no longer signiﬁcant. There were no signiﬁcant
changes in sMg or uMg in the placebo group from week
0 toweeks 4 and 8. The effect of time and intervention on
iMg was not statistically signiﬁcant (Table 3), but there
was a signiﬁcant effect of time and intervention on both
sMg and uMg (Table 3).
T50 increased signiﬁcantly in the Mg 30 mmol/d
group compared with baseline at both weeks 4 and 8,
while only increasing signiﬁcantly within the Mg 15
mmol/d group compared with baseline at week 4, and
with no signiﬁcant changes within the placebo group
(Table 4 and Figure 3). There was also a signiﬁcant
effect of time, and intervention on T50 and post hoc
tests revealed that Mg 30 mmol/d produced signiﬁ-
cantly greater changes to T50 over time compared
with placebo or Mg 15 mmol/d (Table 3). Factors
other than Mg known to affect T50 (fetuin-A, PO4,
ionized Ca, albumin, bicarbonate) did not change
signiﬁcantly in either group throughout the trial
(Table 4).
eGFRdid not change signiﬁcantly throughout the trial,
and there were no changes in blood analyses of mineral
metabolism or uPO4 in any of the treatment groups
(Table 5). There was a signiﬁcant effect of time on change
Table 1. Demographic information
Characteristics
Total
(n [ 34)
Placebo
(n [ 12)
Mg 15
mmol/d
(n [ 11)
Mg 30
mmol/d
(n [ 11)
Male sex, no. (%) 28 (82) 12 (100) 9 (82) 7 (64)
White race, no. (%) 33 (97) 11 (92) 11 (100) 11 (100)
Age (yr) 65.9  8.7 70.4  7.7 61.4  10.2 65.4  5.8
Body mass
index (kg/m2)
27.9  4.5 27.5  3.4 27.8  3.0 28.4  6.6
Smoker
Active, no. (%) 9 (26) 2 (16) 4 (36) 3 (27)
Previous, no. (%) 15 (44) 8 (67) 4 (36) 3 (27)
Never, no. (%) 10 (29) 2 (17) 3 (27) 5 (46)
Comorbidities
Diabetes mellitus
Type 1, no. (%) 0 (0) 0 (0) 0 (0) 0 (0)
Type 2, no. (%) 11 (32) 3 (25) 4 (36) 4 (36)
Coronary artery
disease, no. (%)
6 (18) 4 (33) 1 (9) 1 (9)
Heart failure,
no. (%)
1 (3) 1 (8) 0 (0) 0 (0)
Hypertension,
no. (%)
32 (94) 10 (83) 11 (100) 11 (100)
Dyslipidemia,
no. (%)
23 (68) 10 (83) 6 (55) 7 (64)
Cerebrovascular
disease, no. (%)
5 (15) 2 (17) 1 (9) 2 (18)
Peripheral artery
disease, no. (%)
3 (9) 0 (0) 2 (18) 1 (9)
Cause of CKD
Diabetes mellitus
type 2, no. (%)
6 (18) 2 (17) 1 (9) 3 (27)
Hypertension,
no. (%)
8 (24) 4 (33) 3 (27) 1 (9)
Chronic
glomerulonephritis,
no. (%)
9 (27) 5 (42) 4 (36) 0 (0)
Polycystic kidney
disease, no. (%)
2 (6) 0 (0) 0 (0) 2 (18)
Interstitial
nephropathy,
no. (%)
1 (3) 0 (0) 0 (0) 1 (9)
Other, no. (%) 8 (24) 1 (8) 3 (27) 4 (36)
Medical therapy
ACE inhibitor,
no. (%)
12 (35) 5 (42) 3 (27) 4 (36)
ARB, no. (%) 13 (38) 3 (25) 6 (55) 4 (36)
Beta-blocker,
no. (%)
16 (47) 5 (42) 5 (46) 6 (55)
Calcium-channel
blocker, no. (%)
21 (62) 7 (58) 6 (55) 8 (73)
Loop diuretic,
no. (%)
10 (29) 5 (42) 2 (18) 3 (27)
Thiazide-like diuretic,
no. (%)
7 (21) 1 (8) 4 (36) 2 (18)
Statin, no. (%) 19 (56) 8 (67) 5 (46) 6 (55)
Phosphate binder,
no. (%)
3 (9) 2 (17) 1 (9) 0 (0)
25-Hydroxy
vitamin D,
no. (%)
18 (53) 10 (83) 5 (46) 3 (27)
1,25-Dihydroxy
vitamin D, no. (%)
2 (6) 1 (8) 1 (9) 0 (0)
Sodium bicarbonate,
no. (%)
3 (9) 2 (17) 1 (9) 0 (0)
PPI, no. (%) 15 (44) 4 (33) 7 (64) 3 (27)
Table 1. (Continued)
Characteristics
Total
(n [ 34)
Placebo
(n [ 12)
Mg 15
mmol/d
(n [ 11)
Mg 30
mmol/d
(n [ 11)
Amiloride, no. (%) 2 (6) 0 (0) 1 (9) 1 (9)
Spironolactone,
no. (%)
2 (6) 1 (8) 0 (0) 1 (9)
CNI, no. (%) 1 (3) 1 (8) 0 (0) 0 (0)
Systolic blood
pressure (mm Hg)
138.4  14.7 138.8  14.7 139.1  16.5 137.5  14.1
Diastolic blood
pressure (mm Hg)
82.3  9.7 82.3  9.3 83.3  11.4 81.3  9.2
Heart rate beats/min 75.6  14.3 73.9  10.5 78.5  19.4 74.6  12.94
eGFRCKD-EPI
(ml/min per 1.73 m2)
32.6  12.1 29.6  14.4 36.2  12.8 32.3  8.4
Proteinuria (g/d) 1.63  1.38 1.87  1.33 1.76  1.54 1.20  1.30
Hemoglobin (mmol/l) 8.09  0.86 8.15  0.92 8.01  0.96 8.09  0.75
Albumin (g/l) 37.5  3.1 36.2  3.1 38.2  3.2 38.4  2.7
ACE, angiotensin converting enzyme; ARB, angiotensin 2 receptor blocker; CKD, chronic
kidney disease; CNI, calcineurin inhibitor; eGFR, estimated glomerular ﬁltration rate; Mg,
magnesium; PPI, proton pump inhibitor.
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in QTc on electrocardiogram in the Mg 30 mmol/d group,
but this change lost signiﬁcance in post hoc tests (Table 5).
During the course of the trial, one subject in the Mg
15 mmol/d group suffered a transitory ischemic attack
and withdrew from the trial, and one subject in the Mg
30 mmol/d group withdrew because of difﬁculties
swallowing the study medication. Further, one subject
in the Mg 30 mmol/d group had side effects from the
Table 2. Treatment effect on magnesium parameters, one-way ANOVA with repeated measures, and Bonferroni-corrected post hoc tests
Treatment group Week 0 Week 4 Week 8 P value for time effect
Difference
Week 0 versus week 4
Difference
Week 0 versus week 8
Placebo
iMg (mEq/l) 35.3  1.9 34.4  2.5 36.2  2.7 0.11 0.9 (3.1 to 1.4) 0.9 (0.9 to 2.7)
sMg (mmol/l) 0.830  0.084 0.837  0.100 0.808  0.100 0.50 0.007 (0.063 to 0.076) 0.023 (0.112 to 0.067)
uMg (mmol/d) 3.83  1.62 3.92  1.60 3.70  2.82 0.78 0.09 (0.70 to 0.87) 0.13 (1.41 to 1.14)
Mg 15 mmol/d
iMg (mEq/l) 35.3  2.7 36.0  2.3 34.9  2.9 0.40 0.7 (1.3 to 2.7) 0.4 (2.8 to 2.0)
sMg (mmol/l) 0.790  0.119 0.873  0.086 0.863  0.110 0.04* 0.083 (0.041 to 0.144)** 0.073 (0.031 to 0.176)
uMg (mmol/d) 3.51  1.33 5.00  1.67 4.72  1.75 0.003* 1.49 (0.68 to 2.31)** 1.21 (0.15 to 2.58)
Mg 30 mmol/d
iMg (mEq/l) 35.4  2.7 36.2  2.8 36.8  2.5 0.30 0.9 (2.2 to 3.9) 1.5 (0.9 to 3.9)
sMg (mmol/l) 0.739  0.101 0.844  0.103 0.848  0.099 0.001* 0.105 (0.024 to 0.185)** 0.109 (0.026 to 0.192)**
uMg (mmol/d) 3.16  1.23 5.08  1.68 5.43  2.08 0.001* 1.91 (0.84 to 2.99)** 2.27 (0.67 to 3.87)**
Reported as mean  SD for weeks 0, 4, and 8, and mean change with 95% conﬁdence interval for differences between time points.
ANOVA, analysis of variance; CI, conﬁdence interval; Mg, magnesium, iMg, intracellular magnesium; ionMg, ionized magnesium; sMg, serum magnesium; uMg, urine magnesium.
*P < 0.05.
**P < 0.05 after Bonferroni adjustment for multiple comparisons.
Figure 2. (a) Mean change in intracellular magnesium compared with baseline. Error bars ¼ 95% conﬁdence interval. (b) Mean change in
serum magnesium compared with baseline. Error bars ¼ 95% conﬁdence interval. *P < 0.05 after Bonferroni adjustment for multiple com-
parisons. (c) Mean change in 24-hour urine magnesium compared with baseline. Error bars ¼ 95% confidence interval. *P < 0.05 after
Bonferroni adjustment for multiple comparisons.
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medication similar to previously experience from other
medications (abdominal cramps, ﬂushing, and palpita-
tions), and intolerance to one of the tablet constituents
was suspected (most likely talcum). There were 2 cases
of community-acquired pneumonia in the placebo
group that required hospital admissions, and one case
of asthma exacerbation in the Mg 15 mmol/d group
that required treatment with corticosteroids. None of
the adverse events were considered to be due to the
effects of Mg. Incidence of loosening of stool was
identical (2 in each treatment group), but none of
the study participants experienced frank diarrhea.
Table 3. Change compared with baseline for magnesium parameters and serum calciﬁcation propensity, 2-way mixed ANOVA with repeated
measures
Change at week 4
Mean (CI; P value)
Change at week 8
Mean (CI; P value)
Mg 15 mmol/d versus placebo
iMg (mEq/l) 1.59 (4.60 to 1.42; P ¼ 0.41) 1.32 (3.97 to 1.34; P ¼ 0.45)
sMg (mmol/l) 0.076 (0.010 to 0.162; P ¼ 0.09) 0.095 (0.017 to 0.207; P ¼ 0.11)
uMg (mmol/d) 1.55 (0.45 to 2.65; P ¼ 0.005)* 1.59 (0.09 to 3.27; P ¼ 0.07)
T50 (min) 47.7 (1.3 to 94.1; P ¼ 0.43) 29.1 (17.6 to 75.9; P ¼ 0.29)
Mg 30 mmol/d versus placebo
iMg (mEq/l) 1.74 (1.27 to 4.75; P ¼ 0.34) 0.53 (2.12 to 3.18; P ¼ 0.88)
sMg (mmol/l) 0.098 (0.012 to 0.184; P ¼ 0.02)* 0.132 (0.020 to 0.243; P ¼ 0.02)*
uMg (mmol/d) 1.97 (0.90 to 3.04; P < 0.001)* 2.85 (1.21 to 4.49; P ¼ 0.001)*
T50 (min) 59.6 (13.2 to 106.1; P ¼ 0.01)* 56.2 (9.5 to 102.9; P ¼ 0.02)*
Mg 30 mmol/d versus Mg 15 mmol/d
iMg (mEq/l) 0.15 (2.93 to 3.22; P ¼ 0.99) 1.85 (0.86 to 4.55; P ¼ 0.23)
sMg (mmol/l) 0.022 (0.067 to 0.110; P ¼ 0.82) 0.036 (0.078 to 0.151; P ¼ 0.72)
uMg (mmol/d) 0.42 (0.68 to 1.52; P ¼ 0.62) 1.26 (0.39 to 2.90; P ¼ 0.16)
T50 (min) 11.9 (35.5 to 59.3; P ¼ 0.81) 27.1 (20.7 to 74.8; P ¼ 0.36)
P values for the effect of time and intervention: iMg, P ¼ 0.133; sMg, P ¼ 0.016; uMg, P ¼ 0.009; T50, P ¼ 0.011.
ANOVA, analysis of variance; CI, conﬁdence interval; Mg, magnesium; iMg, intracellular magnesium; sMg, serum magnesium; uMg, urine magnesium; T50, serum calcification propensity.
*P < 0.05.
Table 4. Treatment effect on serum calciﬁcation propensity and related factors, one-way ANOVA with repeated measures or Friedman test,
both with Bonferroni-adjusted post hoc tests
Treatment group Week 0 Week 4 Week 8 P value for time effect
Difference
Week 0 versus week 4
Difference
Week 0 versus week 8
Placebo
T50 (min) 298.4  80.8 270.9  75.4 282.6  70.0 0.23 27.5 (76.7 to 21.7) 15.8 (57.2 to 25.6)
ionCa (mmol/l) 1.210  0.054 1.206  0.017 1.230  0.041 0.84 0.005 (0.046 to 0.036) 0.007 (0.044 to 0.029)
sPO4 (mmol/l) 1.040  0.202 1.118  0.246 1.050  0.258 0.33 0.078 (0.054 to 0.210) 0.010 (0.115 to 0.135)
Fetuin-A (g/l) 0.21 (0.16; 0.26) 0.24 (0.13; 0.49) 0.23 (0.13; 0.49) 0.92 0.03 0.02
Albumin (g/l) 36.2  3.1 35.2  4.2 36.1  3.2 0.39 1.0 (3.5 to 1.5) 0.1 (2.0 to 1.8)
HCO3 (mmol/l) 24.4  3.4 24.1  2.5 25.2  2.6 0.42 0.3 (3.2 to 2.5) 0.8 (1.4 to 3.1)
Mg 15 mmol/d
T50 (min) 263.5  59.1 281.2  39.0 276.7  35.0 0.40 17.7 (18.1 to 53.6) 13.3 (29.2 to 55.8)
ionCa (mmol/l) 1.193  0.048 1.191  0.041 1.179  0.050 0.45 0.002 (0.030 to 0.026) 0.014 (0.055 to 0.027)
sPO4 (mmol/l) 1.082  0.239 1.085  0.234 1.085  0.188 0.99 0.003 (0.197 to 0.202) 0.003 (0.232 to 0.238)
Fetuin-A (g/l) 0.22 (0.11; 0.31) 0.28 (0.11; 0.42) 0.27 (0.15; 0.55) 0.53 0.06 0.05
Albumin (g/l) 38.2  3.2 36.8  3.0 37.5  2.7 0.13 1.4 (3.3 to 0.6) 0.7 (2.6 to 1.2)
HCO3 (mmol/l) 25.0  3.7 25.1  3.5 25.7  3.1 0.42 0.1 (1.4 to 1.5) 0.7 (0.8 to 2.3)
Mg 30 mmol/d
T50 (min) 256.0  60.4 285.6  69.1 296.4  63.9 0.004* 29.6 (6.8 to 52.5)** 40.4 (10.9 to 69.9)**
ionCa (mmol/l) 1.20  0.04 1.21  0.04 1.22  0.06 0.18 0.01 (0.04 to 0.02) 0.03 (0.08 to 0.03)
sPO4 (mmol/l) 1.09  0.18 1.09  0.19 1.05  0.20 0.62 0.00 (0.08 to 0.08) 0.04 (0.18 to 0.10)
Fetuin-A (g/l) 0.33 (0.11; 0.50) 0.20 (0.13; 0.38) 0.36 (0.22; 0.47) 0.72 0.13 0.03
Albumin (g/l) 38.4  2.7 38.0  2.1 38.3  1.9 0.77 0.4 (1.5 to 2.2) 0.1 (1.5 to 1.7)
HCO3 (mmol/l) 25.3  1.8 26.2  2.7 26.7  2.0 0.08 0.9 (0.8 to 2.6) 1.4 (0.3 to 3.2)
Reported as mean  SD or median and interquartile range for weeks 0, 4, and 8 (as relevant), and change with 95% conﬁdence interval or absolute change for differences between time
points (as relevant).
ANOVA, analysis of variance; CI, conﬁdence interval; ionCa, ionized calcium; HCO3, bicarbonate; Mg, magnesium; sPO4, serum phosphate; T50, serum calcification propensity.
*P < 0.05.
**P < 0.05 after Bonferroni adjustment for multiple comparisons.
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None of the adverse events were attributed to Mg
supplementation.
DISCUSSION
The main ﬁnding of this clinical trial is that oral Mg
supplementation using slow-release Mg hydroxide
30 mmol/d does not affect iMg as assessed by energy
dispersive X-ray microanalysis after 8 weeks of treat-
ment, despite signiﬁcant increases in sMg and uMg.
Furthermore, this trial has shown for the ﬁrst time that
calciﬁcation propensity T50 can be improved by oral
Mg supplementation in CKD stages 3 and 4.
Study participants were included based on low to
low-normal levels of sMg, and it is plausible that sub-
jects may have been Mg-depleted based on the low iMg
and uMg in all groups at baseline. Thus, Mg supple-
mentation would ﬁrst have to replenish total body Mg
stores before “spilling over” into the serum, which
could explain the relatively modest increase in sMg and
uMg. We speculate that iMg stores increased in other
compartments of the body (e.g., bone or muscle), and
only later in epithelial cells from the sublingual mu-
cosa, which would account for the lack of a treatment
effect on iMg.
Despite 8 weeks of Mg supplementation with
15 mmol/d or 30 mmol/d on top of dietary Mg intake,
uMg was only 4.72 mmol/d and 5.43 mmol/d in the 2
groups at week 8, respectively. Assuming that
approximately one third of ingested Mg is available
Figure 3. Mean change in serum calciﬁcation propensity compared
with baseline. Error bars ¼ 95% conﬁdence interval. *P < 0.05 after
Bonferroni adjustment for multiple comparisons.
Table 5. Treatment effect on mineral metabolism and kidney function, one-way ANOVA with repeated measures or Friedman test
Treatment group Week 0 Week 4 Week 8 P value for time effect
Difference
Week 0 versus week 4
Difference
Week 0 versus week 8
Placebo
eGFR (ml/min) 29.6  14.4 28.1  13.6 29.6  12.6 0.38 1.5 (5.1 to 2.1) 0.0 (3.7 to 3.7)
ionCa (mmol/l) 1.210  0.054 1.206  0.017 1.230  0.041 0.84 0.005 (0.046 to 0.036) 0.007 (0.044 to 0.029)
sPO4 (mmol/l) 1.040  0.202 1.118  0.246 1.050  0.258 0.33 0.078 (0.054 to 0.210) 0.010 (0.115 to 0.135)
uPO4 (mg/d) 2428  751 2588  860 2458  365 0.82 159 (854 to 1173) 30 (651 to 711)
PTH (pmol/l) 10.4 (6.5:16.8) 8.3 (7.0:16.9) 11.6 (7.1:23.3) 0.26 2.1 1.2
25-D3 (nmol/l) 61.0 (48.5; 78.5) 66.5 (53.3; 78.0) 60.5 (56.3; 72.8) 0.34 5.5 0.5
FGF-23 (IU) 98.0 (54.3; 173.8) 153.0 (68.3; 277.0) 112.0 (60.5; 357.3) 0.56 55 14
QTc (ms) 408.3  25.7 413.7  19.7 414.8  14.9 0.74 5.4 (23.5 to 34.3) 6.5 (17.7 to 30.7)
Mg 15 mmol/d
eGFR (ml/min) 36.2  12.8 38.6  15.1 36.6  14.0 0.17 2.5 (1.8 to 6.7) 0.4 (3.2 to 3.9)
ionCa (mmol/l) 1.193  0.048 1.191  0.041 1.179  0.050 0.45 0.002 (0.030 to 0.026) 0.014 (0.055 to 0.027)
sPO4 (mmol/l) 1.082  0.239 1.085  0.234 1.085  0.188 0.99 0.003 (0.197 to 0.202) 0.003 (0.232 to 0.238)
uPO4 (mg/d) 2281  880 2381  647 2450  1045 0.64 100 (414 to 614) 169 (353 to 691)
PTH (pmol/l) 9.3 (4.5; 18.3) 10.1 (5.3; 13.9) 13.8 (5.7; 17.3) 0.34 0.8 4.5
25-D3 (nmol/l) 46.5 (35.5; 65.3) 49.0 (35.8; 54.8) 40.5 (33.8; 63.3) 0.67 3.5 6
FGF-23 (IU) 62 (53; 112) 58 (42; 105) 59 (56; 111) 0.61 4 3
QTc (ms) 421.2  30.3 418.5  23.1 415.9  30.9 0.73 2.7 (17.2 to 11.8) 5.3 (27.8 to 17.2)
Mg 30 mmol/d
eGFR (ml/min) 32.3  8.4 32.6  9.6 31.8  9.6 0.86 0.3 (3.7 to 3.1) 0.5 (3.6 to 4.5)
ionCa (mmol/l) 1.20  0.04 1.21  0.04 1.22  0.06 0.18 0.01 (0.04 to 0.02) 0.03 (0.08 to 0.03)
sPO4 (mmol/l) 1.09  0.18 1.09  0.19 1.05  0.20 0.62 0.00 (0.08 to 0.08) 0.04 (0.10 to 0.18)
uPO4 (mg/d) 2126  537 2027  741 2071  726 0.86 99 (577 to 774) 55 (366 to 476)
PTH (pmol/l) 13.2 (3.3; 17.9) 15.1 (3.4; 19.9) 13.0 (5.8; 15.5) 0.81 1.9 0.2
25-D3 (nmol/l) 63.5 (44.3; 81.0) 64.0 (39.3; 79.3) 58.0 (40.8; 73.0) 0.38 0.5 5.5
FGF-23 (IU) 75 (62; 110) 69 (57; 93) 72 (47; 96) 0.40 6 3
QTc (ms) 427.6  21.2 430.3  22.3 418.3  26.0 0.03* 2.8 (16.4 to 10.9) 9.2 (4.8 to 23.3)
Reported as mean  SD or median and interquartile range for weeks 0, 4, and 8 (as relevant), and change with 95% conﬁdence interval or absolute change for differences between time
points (as relevant).
ANOVA, analysis of variance; 25-D3, 25-hydroxy vitamin D3; CI, confidence interval; ionCa, ionized calcium; sCa, total serum calcium; eGFR, estimated glomerular filtration rate; FGF-23,
intact fibroblast growth factor 23; Mg, magnesium; sPO4, serum phosphate; PTH, parathyroid hormone; uPO4, urine phosphate; QTc, corrected QT interval.
*P < 0.05.
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for absorption, uMg would be expected to be at least
5 mmol/d and 10 mmol/d for the 2 groups, if Mg intake
was balanced by urinary excretion. The relatively
small increases in uMg in the active treatment groups
suggest either reduced Mg absorption in the gut, Mg
retention due to total body Mg depletion, or Mg
retention due to compromised renal Mg excretion.
Proton pump inhibitors reduce intestinal Mg absorp-
tion, and were used by 64% and 27% of subjects in the
15 mmol/d and 30 mmol/d groups, respectively. Thus,
reduced absorption of Mg might have blunted the ef-
fect of Mg supplementation. Faecal Mg was not
measured in this trial, so it was not possible to assess
Mg absorption in the gut.
This is the ﬁrst clinical trial to show that T50 is
improved by Mg supplementation in CKD stages 3 and
4. Notably, there were no signiﬁcant changes to any of
the other factors known to affect T50, suggesting that
the change in T50 was caused by the increase in sMg
alone. Indeed, adding Mg to serum ex vivo is known to
increase T50.
23 The ﬁnal measurement of T50 in the
group treated with Mg 30 mmol/d was similar to that of
healthy adults without CKD,34 and the intervention
shifted the mean T50 about half a SD for patients with
predialysis CKD, which according to previous data
might lead to a 20% risk reduction in all-cause
mortality.24
Mg delays the formation of secondary calciprotein
particles in the T50 test.
23 A recent in vitro study
convincingly demonstrated that secondary (but not
primary) calciprotein particles induce calciﬁcation of
vascular smooth muscle cells,35 suggesting that delay-
ing the time until formation of secondary calciprotein
particles (i.e., increasing T50) might improve calciﬁca-
tion propensity via this mechanism. Thus, T50 appears
to be a modiﬁable risk factor and might be useful not
only for risk assessment, but also for monitoring and
guiding therapy directed at inhibition of Ca/PO4
crystal formation. Whether the improvement of T50
observed in this trial is sustained over a longer treat-
ment period, and whether this translates to a reduction
in clinically relevant outcomes (e.g., cardiovascular
events or all-cause mortality) will have to be studied in
a future randomized clinical trial, which may use
individualized and combined interventions aimed at
improving T50.
Mg supplementation might be expected to lower
sPO4 in the same manner as Mg-containing PO4
binders. We found no signiﬁcant differences in sPO4,
uPO4 or intact FGF23 in any of the groups, suggesting
that Mg supplementation with the formulation used
in this trial does not affect PO4 homeostasis in any
clinically meaningful way. However, the sample size
and increases in sMg were probably not powered to
deﬁnitively rule out any interaction and larger study
populations would be needed to answer this
question.
Mg supplementation has previously been a concern
in CKD and end-stage renal disease because of the risk
of hypermagnesemia due to impaired renal excretion of
Mg. There is general consensus that hypermagnesemia
is likely not symptomatic at sMg < 2.0 mmol/l
36
and that serious complications only occur at sMg
> 3.0 mmol/l. Based on this trial, 8 weeks of Mg
supplementation with slow-release Mg hydroxide is
safe at doses up to 30 mmol/d in subjects with low or
low-normal sMg and eGFR down to 15 ml/min per
1.73 m2 (the lowest eGFR of any subject in this trial).
However, whether there are risks associated with
longer treatment duration or in subjects with higher
levels of sMg was not assessed in this trial.
There are limitations and strengths to the current
trial. Limitations include that energy dispersive X-ray
microanalysis of sublingual epithelial cells was used as
a proxy for iMg, and not bone, vascular, or muscle
biopsy, which are the gold standards for measurement
of Mg levels in these tissues. Also, the method has not
previously been applied to patients with CKD, which
might have confounded the results. Furthermore, the
sample size was small and the trial was of a short
duration. Lastly, the formulation of slow-release Mg
hydroxide used in this trial was chosen because it is
widely used and readily available in Denmark. It is
possible that other Mg formulations with greater
bioavailability would have produced different effects
on measures of Mg and on T50. Strengths of the trial
include its single-center, randomized controlled and
blinded study design.
In conclusion, 8 weeks of Mg supplementation using
slow-release Mg hydroxide 30 mmol/d did not affect
iMg in sublingual epithelial cells. Mg supplementation
improved T50, which might aid in treating systemic
calciﬁcation propensity. Mg supplementation was safe
and well tolerated with no adverse events related to Mg
treatment and no incidences of symptomatic hyper-
magnesemia. Slow-release Mg hydroxide 30 mmol/d
might therefore be useful for increasing sMg in future
clinical trials addressing vascular calciﬁcation or
calciﬁcation propensity in CKD stages 3 and 4.
DISCLOSURE
BS is the Research Director and President of IntraCellular
Diagnostics, Inc., Medford, OR, USA. AP is one of the co-
inventors of the T50 test and is the CEO and co-founder
of Calciscon AG, Bern, Switzerland, which specializes in
performing the T50 test. Gunnar Kjems ApS provided the
study medication free of charge, but had no role in study
design, data collection and analysis, decision to publish, or
I Bressendorff et al.: Oral Magnesium Supplementation in CKD Stages 3 and 4 CLINICAL RESEARCH
Kidney International Reports (2017) 2, 380–389 387
preparation of the manuscript. All the other authors
declared no competing interests.
REFERENCES
1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic
kidneydisease in theUnitedStates.JAMA. 2007;298:2038–2047.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and
the risks of death, cardiovascular events, and hospitalization.
N Engl J Med. 2004;351:1296–1305.
3. Moe SM, Chen NX. Mechanisms of vascular calciﬁcation in
chronic kidney disease. J Am Soc Nephrol. 2008;19:213–216.
4. London GM, Guerin AP, Marchais SJ, et al. Arterial media
calciﬁcation in end-stage renal disease: impact on all-cause
and cardiovascular mortality. Nephrol Dial Transplant.
2003;18:1731–1740.
5. Van Laecke S, Nagler EV, Verbeke F, et al. Hypomagnesemia
and the risk of death and GFR decline in chronic kidney dis-
ease. Am J Med. 2013;126:825–831.
6. Sakaguchi Y, Fujii N, Shoji T, et al. Hypomagnesemia is a
signiﬁcant predictor of cardiovascular and non-
cardiovascular mortality in patients undergoing hemodialy-
sis. Kidney Int. 2014;85:174–181.
7. Sakaguchi Y, Fujii N, Shoji T, et al. Magnesium modiﬁes the
cardiovascular mortality risk associated with hyper-
phosphatemia in patients undergoing hemodialysis: a cohort
study. PloS One. 2014;9:e116273.
8. Kanbay M, Yilmaz MI, Apetrii M, et al. Relationship between
serummagnesium levels and cardiovascular events in chronic
kidney disease patients. Am J Nephrol. 2012;36:228–237.
9. Ishimura E, Okuno S, Yamakawa T, et al. Serum magnesium
concentration is a signiﬁcant predictor of mortality in mainte-
nance hemodialysis patients.Magnes Res. 2007;20:237–244.
10. Joao Matias P, Azevedo A, Laranjinha I, et al. Lower serum
magnesium is associated with cardiovascular risk factors and
mortality in haemodialysis patients. Blood Purif. 2014;38:
244–252.
11. Fein P, Weiss S, Ramos F, et al. Serum magnesium concen-
tration is a signiﬁcant predictor of mortality in peritoneal
dialysis patients. Adv Perit Dial. 2014;30:90–93.
12. Kurita N, Akizawa T, Fukagawa M, et al. Contribution of
dysregulated serum magnesium to mortality in hemodialysis
patients with secondary hyperparathyroidism: a 3-year
cohort study. Clin Kidney J. 2015;8:744–752.
13. de Roij van Zuijdewijn CL, Grooteman MP, Bots ML, et al.
Serum magnesium and sudden death in European hemodi-
alysis patients. PloS One. 2015;10:e0143104.
14. Sakaguchi Y, Iwatani H, Hamano T, et al. Magnesium mod-
iﬁes the association between serum phosphate and the risk
of progression to end-stage kidney disease in patients with
non-diabetic chronic kidney disease. Kidney Int. 2015;88:
833–842.
15. Massy ZA, Drueke TB. Magnesium and cardiovascular com-
plications of chronic kidney disease. Nat Rev Nephrol.
2015;11:432–442.
16. Montezano AC, Zimmerman D, Yusuf H, et al. Vascular
smooth muscle cell differentiation to an osteogenic pheno-
type involves TRPM7 modulation by magnesium. Hyperten-
sion. 2010;56:453–462.
17. Kircelli F, Peter ME, Sevinc Ok E, et al. Magnesium reduces
calciﬁcation in bovine vascular smooth muscle cells in a
dose-dependent manner. Nephrol Dial Transplant. 2012;27:
514–521.
18. Louvet L, Buchel J, Steppan S, et al. Magnesium prevents
phosphate-induced calciﬁcation in human aortic vascular
smooth muscle cells. Nephrol Dial Transplant. 2013;28:
869–878.
19. Montes de Oca A, Guerrero F, Martinez-Moreno JM, et al.
Magnesium inhibits Wnt/beta-catenin activity and reverses
the osteogenic transformation of vascular smooth muscle
cells. PloS One. 2014;9:e89525.
20. Zelt JG, McCabe KM, Svajger B, et al. Magnesium modiﬁes
the impact of calcitriol treatment on vascular calciﬁcation in
experimental chronic kidney disease. J Pharmacol Exp Ther.
2015;355:451–462.
21. Turgut F, Kanbay M, Metin MR, et al. Magnesium supple-
mentation helps to improve carotid intima media thickness in
patients on hemodialysis. Int Urol Nephrol. 2008;40:
1075–1082.
22. Mortazavi M, Moeinzadeh F, Saadatnia M, et al. Effect of
magnesium supplementation on carotid intima-media thick-
ness and ﬂow-mediated dilatation among hemodialysis
patients: a double-blind, randomized, placebo-controlled trial.
Eur Neurol. 2013;69:309–316.
23. Pasch A, Farese S, Graber S, et al. Nanoparticle-based test
measures overall propensity for calciﬁcation in serum. J Am
Soc Nephrol. 2012;23:1744–1752.
24. Smith ER, Ford ML, Tomlinson LA, et al. Serum calciﬁcation
propensity predicts all-cause mortality in predialysis CKD.
J Am Soc Nephrol. 2014;25:339–348.
25. Keyzer CA, de Borst MH, van den Berg E, et al. Calciﬁcation
propensity and survival among renal transplant recipients.
J Am Soc Nephrol. 2016;27:239–248.
26. Dahle DO, Asberg A, Hartmann A, et al. Serum calciﬁcation
propensity is a strong and independent determinant of car-
diac and all-cause mortality in kidney transplant recipients.
Am J Transplant. 2016;16:204–212.
27. Silver BB. Development of cellular magnesium nano-analysis
in treatment of clinical magnesium deﬁciency. J Am Coll
Nutr. 2004;23:732S–737S.
28. Haigney MC, Silver B, Tanglao E, et al. Noninvasive mea-
surement of tissue magnesium and correlation with cardiac
levels. Circulation. 1995;92:2190–2197.
29. Shechter M, Sharir M, Labrador MJ, et al. Oral magnesium
therapy improves endothelial function in patients
with coronary artery disease. Circulation. 2000;102:
2353–2358.
30. Shechter M, Bairey Merz CN, Stuehlinger HG, et al. Effects of
oral magnesium therapy on exercise tolerance, exercise-
induced chest pain, and quality of life in patients with coro-
nary artery disease. Am J Cardiol. 2003;91:517–521.
31. McBride BF, Min B, Kluger J, et al. An evaluation of the
impact of oral magnesium lactate on the corrected QT inter-
val of patients receiving sotalol or dofetilide to prevent atrial
or ventricular tachyarrhythmia recurrence. Ann Noninvasive
Electrocardiol. 2006;11:163–169.
32. Pokan R, Hofmann P, von Duvillard SP, et al. Oral magnesium
therapy, exercise heart rate, exercise tolerance, and
CLINICAL RESEARCH I Bressendorff et al.: Oral Magnesium Supplementation in CKD Stages 3 and 4
388 Kidney International Reports (2017) 2, 380–389
myocardial function in coronary artery disease patients. Br J
Sports Med. 2006;40:773–778.
33. Shechter M, Saad T, Shechter A, et al. Comparison of mag-
nesium status using X-ray dispersion analysis following
magnesium oxide and magnesium citrate treatment of
healthy subjects. Magnes Res. 2012;25:28–39.
34. de Seigneux S, Ponte B, Berchtold L, et al. Living kidney
donation does not adversely affect serum calciﬁcation
propensity and markers of vascular stiffness. Transpl Int.
2015;28:1074–1080.
35. Aghagolzadeh P, Bachtler M, Bijarnia R, et al. Calciﬁcation of
vascular smooth muscle cells is induced by secondary calci-
protein particles and enhanced by tumor necrosis factor-
alpha. Atherosclerosis. 2016;251:404–414.
36. Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin
Kidney J. 2012;5(Suppl 1):i3–i14.
I Bressendorff et al.: Oral Magnesium Supplementation in CKD Stages 3 and 4 CLINICAL RESEARCH
Kidney International Reports (2017) 2, 380–389 389
